No Data
No Data
Dorui Pharmaceuticals: Report for the first quarter of 2025
Duori Pharmaceutical (301075.SZ): Compound Sodium Acetate Ringer's Injection has obtained the Pharmaceutical registration certificate.
On April 22, Gelonghui reported that Duorui Pharmaceutical (301075.SZ) announced that its wholly-owned subsidiary Hubei Duorui Pharmaceutical Co., Ltd. has recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration for the compound sodium acetate Ringer's injection. The indications for the compound sodium acetate Ringer's injection are supplementation of extracellular fluid during decreased circulating blood volume and interstitial fluid, and correction of metabolic acidosis.
Express News | Duori Pharmaceutical: 0.7 million shares released from pledge.
Dorui Pharmaceuticals: 2024 Annual Report
Doray Pharmaceuticals: 2024 Annual Report Summary
Dorey Pharmaceutical (301075.SZ): A net loss of 62.6667 million yuan for the year 2024.
On April 17, Gelonghui reported that Duolai Pharmaceutical (301075.SZ) released its annual report for 2024, revealing that the company achieved a revenue of 0.241 billion yuan, a year-on-year decrease of 28.02%; the net income attributable to shareholders of the listed company was -62.6667 million yuan, turning from profit to loss year-on-year; the net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -66.4545 million yuan; the EPS was -0.79 yuan.